vs
ARBOR REALTY TRUST INC（ABR）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ARBOR REALTY TRUST INC的1.5倍（$199.9M vs $133.4M），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -12.1%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -8.9%）
Arbor Realty Trust Inc.是总部位于美国的专业房地产投资信托（REIT）企业，主要为多户住宅及商业地产项目提供结构性融资服务，涵盖过渡贷款、机构贷款、夹层融资等品类，服务覆盖美国各地的地产持有者、开发商及房产投资群体。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ABR vs APLS — 直观对比
营收规模更大
APLS
是对方的1.5倍
$133.4M
营收增速更快
APLS
高出6.1%
-12.1%
两年增速更快
APLS
近两年复合增速
-8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $133.4M | $199.9M |
| 净利润 | — | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -25.6% |
| 净利率 | — | -29.5% |
| 营收同比 | -12.1% | -5.9% |
| 净利润同比 | — | -62.2% |
| 每股收益（稀释后） | $0.08 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABRAPLS
| Q4 25 | $133.4M | $199.9M | ||
| Q3 25 | $112.4M | $458.6M | ||
| Q2 25 | $130.4M | $178.5M | ||
| Q1 25 | $134.2M | $166.8M | ||
| Q4 24 | $151.7M | $212.5M | ||
| Q3 24 | $156.7M | $196.8M | ||
| Q2 24 | $153.1M | $199.7M | ||
| Q1 24 | $160.7M | $172.3M |
净利润ABRAPLS
| Q4 25 | — | $-59.0M | ||
| Q3 25 | $52.0M | $215.7M | ||
| Q2 25 | $36.3M | $-42.2M | ||
| Q1 25 | $43.4M | $-92.2M | ||
| Q4 24 | — | $-36.4M | ||
| Q3 24 | $73.5M | $-57.4M | ||
| Q2 24 | $61.8M | $-37.7M | ||
| Q1 24 | $73.2M | $-66.4M |
营业利润率ABRAPLS
| Q4 25 | — | -25.6% | ||
| Q3 25 | — | 48.7% | ||
| Q2 25 | — | -18.6% | ||
| Q1 25 | — | -50.0% | ||
| Q4 24 | — | -12.3% | ||
| Q3 24 | — | -24.0% | ||
| Q2 24 | — | -14.7% | ||
| Q1 24 | 46.9% | -36.0% |
净利率ABRAPLS
| Q4 25 | — | -29.5% | ||
| Q3 25 | 46.3% | 47.0% | ||
| Q2 25 | 27.8% | -23.6% | ||
| Q1 25 | 32.3% | -55.3% | ||
| Q4 24 | — | -17.1% | ||
| Q3 24 | 46.9% | -29.2% | ||
| Q2 24 | 40.4% | -18.9% | ||
| Q1 24 | 45.6% | -38.5% |
每股收益（稀释后）ABRAPLS
| Q4 25 | $0.08 | $-0.40 | ||
| Q3 25 | $0.20 | $1.67 | ||
| Q2 25 | $0.12 | $-0.33 | ||
| Q1 25 | $0.16 | $-0.74 | ||
| Q4 24 | $0.31 | $-0.30 | ||
| Q3 24 | $0.31 | $-0.46 | ||
| Q2 24 | $0.25 | $-0.30 | ||
| Q1 24 | $0.31 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $482.9M | $466.2M |
| 总债务越低越好 | $11.1B | — |
| 股东权益账面价值 | $3.0B | $370.1M |
| 总资产 | $14.5B | $1.1B |
| 负债/权益比越低杠杆越低 | 3.75× | — |
8季度趋势，按日历期对齐
现金及短期投资ABRAPLS
| Q4 25 | $482.9M | $466.2M | ||
| Q3 25 | $423.4M | $479.2M | ||
| Q2 25 | $255.7M | $370.0M | ||
| Q1 25 | $308.8M | $358.4M | ||
| Q4 24 | $503.8M | $411.3M | ||
| Q3 24 | $687.5M | $396.9M | ||
| Q2 24 | $737.5M | $360.1M | ||
| Q1 24 | $908.0M | $325.9M |
总债务ABRAPLS
| Q4 25 | $11.1B | — | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $10.1B | — | ||
| Q1 25 | $9.9B | — | ||
| Q4 24 | $10.0B | — | ||
| Q3 24 | $10.3B | — | ||
| Q2 24 | $10.6B | — | ||
| Q1 24 | $11.4B | $93.1M |
股东权益ABRAPLS
| Q4 25 | $3.0B | $370.1M | ||
| Q3 25 | $3.0B | $401.2M | ||
| Q2 25 | $3.0B | $156.3M | ||
| Q1 25 | $3.0B | $164.2M | ||
| Q4 24 | $3.0B | $228.5M | ||
| Q3 24 | $3.0B | $237.1M | ||
| Q2 24 | $3.1B | $264.3M | ||
| Q1 24 | $3.1B | $266.7M |
总资产ABRAPLS
| Q4 25 | $14.5B | $1.1B | ||
| Q3 25 | $13.9B | $1.1B | ||
| Q2 25 | $13.6B | $821.4M | ||
| Q1 25 | $13.4B | $807.3M | ||
| Q4 24 | $13.5B | $885.1M | ||
| Q3 24 | $13.9B | $901.9M | ||
| Q2 24 | $14.2B | $904.5M | ||
| Q1 24 | $15.1B | $831.9M |
负债/权益比ABRAPLS
| Q4 25 | 3.75× | — | ||
| Q3 25 | 3.47× | — | ||
| Q2 25 | 3.40× | — | ||
| Q1 25 | 3.29× | — | ||
| Q4 24 | 3.29× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | 3.47× | — | ||
| Q1 24 | 3.68× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $372.4M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-14.3M |
| 自由现金流率自由现金流/营收 | — | -7.1% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $45.0M |
8季度趋势，按日历期对齐
经营现金流ABRAPLS
| Q4 25 | $372.4M | $-14.2M | ||
| Q3 25 | $178.7M | $108.5M | ||
| Q2 25 | $60.0M | $4.4M | ||
| Q1 25 | $150.5M | $-53.4M | ||
| Q4 24 | $461.5M | $19.4M | ||
| Q3 24 | $85.0M | $34.1M | ||
| Q2 24 | $69.9M | $-8.3M | ||
| Q1 24 | $260.0M | $-133.0M |
自由现金流ABRAPLS
| Q4 25 | — | $-14.3M | ||
| Q3 25 | — | $108.3M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $-53.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-8.4M | ||
| Q1 24 | — | $-133.3M |
自由现金流率ABRAPLS
| Q4 25 | — | -7.1% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | -32.0% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -4.2% | ||
| Q1 24 | — | -77.3% |
资本支出强度ABRAPLS
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.2% |
现金转化率ABRAPLS
| Q4 25 | — | — | ||
| Q3 25 | 3.44× | 0.50× | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 3.47× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.16× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 3.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABR
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
